TABLE 2.
Baseline demographics and clinical characteristics
| Part 2 | |||
|---|---|---|---|
| Part 1 | Subantibiotic dose oral doxycycline (SDD40) | Placebo | |
| Enrolled | 235 | 65 | 65 |
| Gender, n (%) | |||
| Male | 66 (28.7%) | 20 (30.8%) | 24 (36.9%) |
| Female | 164 (71.3%) | 45 (69.2%) | 41 (63.1%) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 44 (19.1%) | 12 (18.5%) | 14 (21.5%) |
| Not Hispanic or Latino | 186 (80.9%) | 53 (81.5%) | 51 (78.5%) |
| Race, n (%) | |||
| White | 217 (94.3%) | 63 (96.9%) | 63 (96.9%) |
| Black/African American | 7 (3.0%) | 0 (0.0%) | 1 (1.5%) |
| Asian | 1 (0.4%) | 1 (1.5%) | 0 (0.0%) |
| Other | 5 (2.2%) | 1 (1.5%) | 1 (1.5%) |
| Age, mean years (SD) | 47.4 (12.9) | 47.2 (13.2) | 51.7 (12.8) |
| Skin type (n, %) | |||
| Dry | 40 (17.4%) | 12 (18.5%) | 15 (26.8%) |
| Normal | 50 (21.7%) | 9 (13.8%) | 8 (14.3%) |
| Oily | 38 (16.5%) | 9 (13.8%) | 12 (21.4%) |
| Combination | 102 (44.3%) | 35 (53.8%) | 21 (37.5%) |
| Fitzpatrick skin type (n,%) | |||
| I | 16 (7.0%) | 2 (3.1%) | 3 (5.4%) |
| II | 93 (40.4%) | 26 (40.0%) | 25 (44.6%) |
| III | 64 (27.8%) | 22 (33.8%) | 14 (25.0%) |
| IV | 42 (18.3%) | 11 (16.9%) | 11 (19.6%) |
| V | 15 (6.5%) | 4 (6.2%) | 3 (5.4%) |
| VI | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Baseline IGA, n (%) | |||
| Clear | 0 | 34 (52.3%) | 32 (49.2%) |
| Near clear | 0 | 22 (33.8%) | 24 (36.9%) |
| Mild | 0 | 9 (13.8%) | 9 (13.8%) |
| Moderate | 149 (64.8%) | 0 | 0 |
| Severe | 81 (35.2%) | 0 | 0 |
| Missing | 0 | 0 | 0 |
| Baseline inflammatory lesions | |||
| Mean | 19.8 | 1.2 | 1.3 |
| SD | 7.4 | 1.7 | 1.9 |
| Median | 18.0 | 0.0 | 1.0 |
| Range (min, max) | (11, 40) | (0, 8) | (0, 10) |